As the first H1N1 vaccine arrives in clinics this week, the mainstream media are once again cranking up their swine flu coverage. CNBC is devoting more airtime and CNBC.com is allocating more space to the topic as well, but most of the stuff is a little more niche focused for an investor and business audience.
Yesterday and today thousands of kids and healthcare workers around the country started getting AstraZeneca's H1N1 FluMist, the vaccine that's sprayed into the nose. The first shots from Novartis and Sanofi-Aventis may be available later this week. GlaxoSmithKline and Baxter are still waiting for the FDA to approve their vaccines.